Besides CD134 and CD137 functional markers, we recently assessed the expression of additional activation and cytotoxicity markers by CCCs/SARS-CoV-2-cross-reactive CD4+ and CD8+ T cells from COVID-19 patients and healthy individuals (1). This evidence concerns the gene TNFRSF9 and COVID-19.